Stifel Maintains Buy on OptimizeRx, Raises Price Target to $12.5

Benzinga · 05/13 16:26
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $8 to $12.5.